Any failure to comply with this restriction may constitute a violation of U.S. Newswire Services or for dissemination in the United States. For more information visit for distribution to U.S. We provide access to safe, legal psychedelic experiences, while advancing research for psychedelic medicine. Novamind is building a global network of clinics and retreats that are required for a regulated psychedelics industry. For more information visit About Novamind
Both organizations are based near Salt Lake City, Utah, and are committed to evidence-based psychedelic healing. Cedar Clinical Research is a dedicated research organization focused on advancing psychedelic medicine. Novamind is evaluating a pipeline of early-stage clinical research opportunities and expects to announce preclinical work on a psychedelic therapeutic protocol during Q3 2020.Ībout Cedar Psychiatry and Cedar Clinical ResearchĬedar Psychiatry is an innovative provider of outpatient mental health services, operating psychiatry clinics specialized in ketamine-assisted psychotherapy. CCR operates at the leading edge of evidence-based care and is currently conducting a variety of clinical research studies examining conditions including depression, eating disorders, PTSD , and end-of-life anxiety.Ĭedar Clinical Research is initiating its own research studies, integrating the data and learnings gained from patient treatment experiences and outcomes at Cedar Psychiatry, as well as related international retreats, to advance research on psychedelic medicine. Food and Drug Administration (FDA) approval of SpravatoTM. Robison led the Utah site for the pivotal ketamine study for treatment-resistant depression by Janssen, leading to the U.S. From its dedicated research center in Springville, Utah, CCR has developed a strong track record providing contract research (CRO) services, including hosting clinical trials. Through Novamind's global network of clinics and retreats (operating exclusively in jurisdictions where certain psychedelics are legal), Cedar Psychiatry anticipates expanding its service offerings to provide patients with increased access to psychedelic medicine, along with screening, preparation, and integration services.Ĭedar Clinical Research (" CCR") now leads Novamind's clinical research activities. Robison supervises and trains ketamine-assisted psychotherapy practitioners at Cedar Psychiatry's clinics across Utah, and to date has guided thousands of ketamine therapy journeys and hundreds of SpravatoTM treatment sessions. Robison established a ketamine infusion practice at Intermountain Medical Center, Utah's largest hospital. He was one of the first clinicians to use ketamine off-label for the treatment of depression in Utah. Robison is a thought leader in ketamine-assisted psychotherapy and psychedelic-medicine. In addition, Cedar Psychiatry is a leading provider of ketamine therapy, having administered over 3,000 ketamine-assisted psychotherapy sessions and over 700 SpravatoTM (esketamine) treatments since its inception. Founded in 2016, Cedar Psychiatry operates four outpatient mental health clinics near Salt Lake City, Utah, providing a wide range of services including psychotherapy, diagnostic evaluations, pharmacogenetic testing, psychiatric medication management and transcranial magnetic stimulation (TMS). With the closing of the Cedar Acquisitions, Reid Robison, MD, MBA, co-founder of Cedar Psychiatry and Cedar Clinical Research, will join Novamind's senior leadership team.Ĭedar Psychiatry is now the central hub of Novamind's global network of clinics and retreats offering legal, medically supervised psychedelic experiences. (" Novamind"), a mental health and wellness company specialized in psychedelic-assisted psychotherapy, is pleased to announce that it has closed the acquisitions of Cedar Psychiatry LLC (" Cedar Psychiatry"), a specialized provider of ketamine-assisted psychotherapy and Cedar Clinical Research LLC (" Cedar Clinical Research"), a dedicated research center focused on psychedelic medicines, both based near Salt Lake City, Utah. TORONTO, ON / ACCESSWIRE / J/ Novamind Ventures Inc.
0 kommentar(er)
